Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

By O. Ringdén, M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, H. Lönnies, Hanns-Ulrich Marschall, A. Dlugosz, A. Szakos, Z. Hassan and 4 more. Transplantation, 2006

1,134 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/da3c6a228a56c74117cd9c987b8b4afdb07a300a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Lalu
2. J. Granton
3. Hongda Ji
4. H. Tse
5. D. Fergusson
6. L. Chen
7. Z. Zhang
8. J. Michálek

Citations in the corpus

• Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, positive): “Moreover, both haploidentical and third-party (HLA-mismatched) BM-MSCs can be safely and effectively used to treat de novo and steroid-resistant acute GvHD [118,200,202–205].”
• Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, methodology): “[17,18,26,27,29,31,33,35] Five studies explicitly reported and separated serious from non-serious adverse events; [13,14,20,24,46] two of these referenced a standardized approach to detailing adverse events developed by other organizations.”
• Mesenchymal stem cells and immunomodulation: current status and future prospects (2016, background): “5 ×10(6) to 10×10(6)/kg of the recipients or even higher)(105) as well as the frequency (single versus multiple injections).(81,88,126,127) Although MSCs are thought to be immunoprivileged, repeated infusion of mismatched”